Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

08.11.2021

1 Am J Gastroenterol
1 Am J Pathol
2 Anticancer Res
9 BMC Cancer
1 BMC Gastroenterol
2 Cancer Res
2 Clin Res Hepatol Gastroenterol
2 Dig Dis Sci
1 Endoscopy
4 Hepatology
8 J Gastroenterol Hepatol
16 J Hepatol
5 Minerva Gastroenterol (Torino)
2 PLoS One
1 Radiol Imaging Cancer
5 Transplantation



    Am J Gastroenterol

  1. DUONG NK, Shrestha S, Park D, Shahab O, et al
    Bristol Stool Scale as a Determinant of Hepatic Encephalopathy Management in Patients With Cirrhosis.
    Am J Gastroenterol. 2021 Nov 5. pii: 00000434-990000000-00135.
    >> Share


    Am J Pathol

  2. CHAO X, Wang S, Hlobik M, Ballabio A, et al
    Loss of Hepatic Transcription Factor EB Attenuates Alcohol-Associated Liver Carcinogenesis.
    Am J Pathol. 2021 Oct 27. pii: S0002-9440(21)00442.
    >> Share


    Anticancer Res

  3. OMIYA S, Komatsu S, Kido M, Kuramitsu K, et al
    Impact of Sarcopenia as a Prognostic Factor on Reductive Hepatectomy for Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:5775-5783.
    >> Share

  4. IMAI N, Yokoyama S, Yamamoto K, Ito T, et al
    Safety and Efficacy of Glass Membrane Pumping Emulsification Device in Transarterial Chemoembolization for Hepatocellular Carcinoma: First Clinical Outcomes.
    Anticancer Res. 2021;41:5817-5820.
    >> Share


    BMC Cancer

  5. FU Y, Wei X, Han Q, Le J, et al
    Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    BMC Cancer. 2021;21:1165.
    >> Share

  6. DING J, Wen Z
    Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
    BMC Cancer. 2021;21:1157.
    >> Share

  7. WANG F, Numata K, Takeda A, Ogushi K, et al
    Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
    BMC Cancer. 2021;21:1169.
    >> Share

  8. BO J, Peng H, LianHua Z, Xiang F, et al
    Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol.
    BMC Cancer. 2021;21:1171.
    >> Share

  9. GAO S, Gang J, Yu M, Xin G, et al
    Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer.
    BMC Cancer. 2021;21:791.
    >> Share

  10. VOGLHUBER T, Eitz KA, Oechsner M, Vogel MME, et al
    Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival.
    BMC Cancer. 2021;21:780.
    >> Share

  11. SUN X, Mei J, Lin W, Yang Z, et al
    Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
    BMC Cancer. 2021;21:775.
    >> Share

  12. SONG D, Hu Y, Diao B, Miao R, et al
    Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer.
    BMC Cancer. 2021;21:798.
    >> Share

  13. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.
    BMC Cancer. 2021;21:699.
    >> Share


    BMC Gastroenterol

  14. WU SY, Liao P, Yan LY, Zhao QY, et al
    Correlation of MKI67 with prognosis, immune infiltration, and T cell exhaustion in hepatocellular carcinoma.
    BMC Gastroenterol. 2021;21:416.
    >> Share


    Cancer Res

  15. GONZALEZ-ROMERO F, Mestre D, Aurrekoetxea I, O'Rourke CJ, et al
    E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
    Cancer Res. 2021;81:2874-2887.
    >> Share

  16. LULLI M, Del Coco L, Mello T, Sukowati C, et al
    DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer.
    Cancer Res. 2021;81:2861-2873.
    >> Share


    Clin Res Hepatol Gastroenterol

  17. PETA V, Zhu J, Lubman DM, Huguet S, et al
    Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
    >> Share

  18. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
    Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101556.
    >> Share


    Dig Dis Sci

  19. PODRUG K, Trkulja V, Zelenika M, Bokun T, et al
    Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
    Dig Dis Sci. 2021 Nov 5. pii: 10.1007/s10620-021-07277.
    >> Share

  20. BENITEZ C
    Pressure Measurements Under Pressure: Simplifying the Diagnosis of Clinically Significant Portal Hypertension.
    Dig Dis Sci. 2021 Nov 5. pii: 10.1007/s10620-021-07283.
    >> Share


    Endoscopy

  21. SHIRATORI Y, Yoshimoto T, Yamamoto K
    Esophageal variceal treatment using a novel Doppler probe method.
    Endoscopy. 2021;53:E419-E420.
    >> Share


    Hepatology

  22. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    >> Share

  23. LAN T, Jiang S, Zhang J, Weng Q, et al
    Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-beta-activated Kinase 1-dependent Signaling.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32221.
    >> Share

  24. DING MJ, Fang HR, Zhang JK, Shi JH, et al
    E3 ubiquitin ligase RNF5 protects against hepatic ischemia reperfusion injury by mediating PGAM5 ubiquitination.
    Hepatology. 2021 Nov 4. doi: 10.1002/hep.32226.
    >> Share

  25. ROSENBLATT R, Lee H, Liapakis A, Lunsford KE, et al
    Equitable access to liver transplant: Bridging the gaps in the social determinants of health.
    Hepatology. 2021 Jun 1. doi: 10.1002/hep.31986.
    >> Share


    J Gastroenterol Hepatol

  26. RHODES FA, Trembling P, Panovska-Griffiths J, Tanwar S, et al
    Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
    J Gastroenterol Hepatol. 2021;36:1435-1449.
    >> Share

  27. LV T, Chen S, Li M, Zhang D, et al
    Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1423-1434.
    >> Share

  28. KIM BH, Yu SJ, Kang W, Cho SB, et al
    Expert Consensus on the Management of Adverse Events in Patients Receiving Lenvatinib for Hepatocellular Carcinoma.
    J Gastroenterol Hepatol. 2021 Nov 1. doi: 10.1111/jgh.15727.
    >> Share

  29. HUANG Y, Huang F, Yang L, Hu W, et al
    Development and validation of a radiomics signature as a non-invasive complementary predictor of gastroesophageal varices and high-risk varices in compensated advanced chronic liver disease: A multicenter study.
    J Gastroenterol Hepatol. 2021;36:1562-1570.
    >> Share

  30. LIU D, Shen Y, Zhang R, Xun J, et al
    Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    J Gastroenterol Hepatol. 2021;36:1670-1678.
    >> Share

  31. AHADI M, Molooghi K, Masoudifar N, Namdar AB, et al
    A review of non-alcoholic fatty liver disease in non-obese and lean individuals.
    J Gastroenterol Hepatol. 2021;36:1497-1507.
    >> Share

  32. HASSANI ZADEH S, Mansoori A, Hosseinzadeh M
    Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2021;36:1470-1478.
    >> Share

  33. CHUN HS, Lee JS, Lee HW, Kim BK, et al
    Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes.
    J Gastroenterol Hepatol. 2021;36:1703-1713.
    >> Share


    J Hepatol

  34. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    >> Share

  35. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    >> Share

  36. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    >> Share

  37. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    >> Share

  38. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    >> Share

  39. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    >> Share

  40. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    >> Share

  41. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    >> Share

  42. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    >> Share

  43. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    >> Share

  44. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    >> Share

  45. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    >> Share

  46. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    >> Share

  47. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    >> Share

  48. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    >> Share

  49. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    >> Share


    Minerva Gastroenterol (Torino)

  50. SCIARRONE SS, Zanetto A, Russo FP, Germani G, et al
    Malnourished cirrhotic patient: what should we do?
    Minerva Gastroenterol (Torino). 2021;67:11-22.
    >> Share

  51. TESTINO G, Pellicano R
    Acute-on-chronic liver failure by SARS-CoV-2 in active alcohol use disorder cirrhotic patient.
    Minerva Gastroenterol (Torino). 2021;67:283-288.
    >> Share

  52. ZANETTO A, Barbiero G, Battistel M, Sciarrone SS, et al
    Management of portal hypertension severe complications.
    Minerva Gastroenterol (Torino). 2021;67:26-37.
    >> Share

  53. FERRARESE A, Sciarrone SS, Pellone M, Shalaby S, et al
    Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma.
    Minerva Gastroenterol (Torino). 2021;67:4-10.
    >> Share

  54. GERMANI G, Battistella S, Ulinici D, Zanetto A, et al
    Drug induced liver injury: from pathogenesis to liver transplantation.
    Minerva Gastroenterol (Torino). 2021;67:50-64.
    >> Share


    PLoS One

  55. HE Y, Xu R, Peng L, Hu X, et al
    Tumor infiltrating lymphocytes associated competitive endogenous RNA networks as predictors of outcome in hepatic carcinoma based on WGCNA analysis.
    PLoS One. 2021;16:e0254829.
    >> Share

  56. DAYTON KA, Bril F, Barb D, Lai J, et al
    Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
    PLoS One. 2021;16:e0251449.
    >> Share


    Radiol Imaging Cancer

  57. TAIJI R, Lin EY, Lin YM, Yevich S, et al
    Combined Angio-CT Systems: A Roadmap Tool for Precision Therapy in Interventional Oncology.
    Radiol Imaging Cancer. 2021;3:e210039.
    >> Share


    Transplantation

  58. WALLACE D, Cowling TE, Walker K, Suddle A, et al
    The Impact of Performance Status on Length of Hospital Stay and Clinical Complications Following Liver Transplantation.
    Transplantation. 2020 Oct 8. doi: 10.1097/TP.0000000000003484.
    >> Share

  59. CARTIN-CEBA R, Burger C, Swanson K, Vargas H, et al
    Clinical Outcomes after Liver Transplantation in Patients with Portopulmonary Hypertension.
    Transplantation. 2020 Oct 12. doi: 10.1097/TP.0000000000003490.
    >> Share

  60. YOELI D, Choudhury RA, Nydam TL, Pomposelli JJ, et al
    The Surge in Deceased Liver Donors Due to the Opioid Epidemic: Is It Time to Split the Difference?
    Transplantation. 2021;105:2239-2244.
    >> Share

  61. JAMAL M, AlMahmeed H, AlGhanem M, AlMatooq M, et al
    Organ Transplantation in Kuwait and the Recent Initiation of a Liver Program.
    Transplantation. 2021;105:2125-2127.
    >> Share

  62. SCHLEGEL A, Foley DP, Savier E, Flores Carvalho M, et al
    Recommendations for Donor and Recipient Selection and Risk Prediction: Working Group Report From the ILTS Consensus Conference in DCD Liver Transplantation.
    Transplantation. 2021;105:1892-1903.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016